VEDOLIZUMAB SHOWS BETTER TREATMENT OUTCOMES THAN INFLIXIMAB FOR PATIENTS WITH ULCERATIVE COLITIS REFRACTORY TO TREATMENT WITH ADALIMUMAB: A PROPENSITY SCORE ANALYSIS OF UK IBD BIORESOURCE OUTCOMES

Christina Kapizioni  ¹     Rofaida Desoki     Miles Parkes     Tim Raine    
¹ Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom

Topic
IBD, Immunology, Paediatrics

Session
IBD: Clinical trials I

Conference
UEG Week Virtual 2021

Citation
United European Gastroenterology Journal 2021; 9 (Supplement 8)